Identification of Human Tissue Kallikrein 6 as a Potential Marker of Laryngeal Cancer Based on the Relevant Secretory/Releasing Protein Database

Table 1

KLK6 levels in the plasma of laryngeal SCC patients and controls.

Characteristics	KLK6 levels (ng/mL)		𝑃 value
	Median	Interquartile range
All individuals	4.76	2.34
Diagnostic category
Healthy	4.65	2.32
Benign	4.65	1.86	0.607*
Cancer	4.90	4.26	0.047^†
			0.014^‡
Anatomical region of cancer
Glottis	4.91	4.06	0.393
Supraglottis	4.88	4.21
Disease stage
I + II	5.44	3.60	0.375
III + IV	4.76	4.48
T stage
T1	6.06	3.87	0.544
T2	4.98	5.00
T3	4.98	4.55
T4	4.60	2.62
Lymph node status
pN0	5.15	3.84	0.507
pN+	4.77	4.49
Tumor differentiation
Well	4.65	5.09	0.637
Moderate	5.33	4.66
Poor	4.59	3.85

KLK6: kallikrein 6.
Comparisons of the plasma KLK6 levels between two independent sample cohorts were assessed by the Mann-Whitney 𝑈 test, and those among more than two independent cohorts were assessed by the Kruskal-Wallis 𝐻 test. *Benign versus health; ^†cancer versus benign; ^‡cancer versus health.